OverviewSuggest Edit

Prognos, formerly known as Medivo, is a healthcare AI company focused on predicting disease. The Company aggregates, normalizes and provides clinical interpretation of clinical diagnostics data at scale, using HIPAA compliant infrastructure. The Company's AI platform enables early prediction of disease onset, therapy need, clinical trial opportunity, care gaps, and risk, using clinical algorithms across a range of conditions.

HQNew York, US
Employee Ratings3.1

Latest Updates

Employees (est.) (May 2019)87(+3%)

Key People/Management at Prognos

Sundeep Bhan

Sundeep Bhan

Co-Founder, CEO
Jason Bhan

Jason Bhan

Co-Founder & Chief Medical Officer
Steve Chase

Steve Chase

Adam Petranovich

Adam Petranovich

Chief Data Scientist
Hilary Weckstein

Hilary Weckstein

General Counsel & Chief Privacy Officer
Theresa Greco

Theresa Greco

Chief Commercial Officer
Show more

Prognos Office Locations

Prognos has an office in New York
New York, US (HQ)
85 Broad St
Show all (1)

Prognos Financials and Metrics

Summary Metrics

Founding Date


Prognos total Funding

$43.2 m

Prognos latest funding size

$20.50 m

Time since last funding

a year ago

Prognos investors

Prognos's latest funding round in November 2017 was reported to be $20.5 m. In total, Prognos has raised $43.2 m
Show all financial metrics

Prognos Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
OnTrack DiabetesSeptember 26, 2013
WellAppsMarch 07, 2012

Prognos Online and Social Media Presence

Embed Graph

Prognos News and Updates

Prognos Launches Signal Solution at DigiPharma Connect Conference

NEW YORK, Feb. 22, 2019 /PRNewswire/ -- Prognos announced the launch of a groundbreaking digital solution today that will help life science brands use real-world diagnostic alerts to treat patients more efficiently. The healthcare AI company will introduce the product at the DigiPharma...

Biocept and Prognos Enter Into Partnership to Apply Artificial Intelligence in Order to Help Pharmaceutical and Life Sciences Companies Optimize Commercialization of Biomarker-Targeted Therapies in Oncology

SAN DIEGO, Dec. 18, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, has entered into a Software License...

Rapport för sexmånadersperioden som avslutades den 30 juni 2018

Beloppen i ovanstående tabell för 2017 avser kvarvarande verksamhet.1Baserat på periodens resultat hänförligt till moderbolagets aktieägare.

Prognos VP says analytics success requires a marriage of business and IT

Denise Olivares explains that women tend to be good at piecing together various data sets, as she does in working with healthcare payers to identify risk within a patient population.

Prognos Blogs

What to Consider if Your Drug is a Targeted Therapy for a New Biomarker

A Follow Up to “Biomarker Testing in Non-Small Cell Lung Cancer“ By Melissa Leonhauser, General Manager, Alert & Targeting Portfolio   More and more targeted cancer therapies are being developed. But, after approval, the brand team faces an uphill battle in getting physicians to test for any new…

Highlights from RISE Nashville 2019

By Asher Gendelman, VP of Payer Sales Once again, RISE Nashville delivered rich content, deep discussions, and fantastic networking. The conference was bigger than ever with roughly 1,400 attendees.  Risk adjustment and quality improvement were the focus topics for about 50% of the conference attend…

Available Omnichannel HCP Data Sources

Clinical Diagnostic Data for Omnichannel HCP Promotion Marketing: Part Two We’re excited to share part two of our blog series about one of the most emerging themes for life science brands to harness: real world clinical diagnostics data to power HCP omni-channel marketing. We’ve broken up our series…

Biomarker Testing in Non-Small Cell Lung Cancer

By Bill Bowman, Clinical Solutions Architect The trend toward precision medicine in oncology is epitomized by the management of patients with metastatic non-small cell lung cancer (mNSCLC).  Multiple molecular targets have been identified and a growing number of brands have become commercially avail…

Clinical Diagnostic Data for Omnichannel HCP Marketing

A 5 Part Series By Matt Apprendi, VP of Digital Products   We’re excited to write about one of the most emerging themes for Life Science brands to harness: real world clinical diagnostics data to power HCP omni-channel marketing.  We’ve decided to break this blog post into five tranches to explore t…

Innovative Models for Converting AI Data

Wouldn’t it be convenient if a doctor could simply upload a patient’s medical chart into an artificial intelligence (AI) system, the computer reads the information, and the AI seamlessly organizes it so it can be easily accessed at a later time? That day may be closer than you think. In just the pas…
Show more

Prognos Frequently Asked Questions

  • When was Prognos founded?

    Prognos was founded in 2010.

  • Who are Prognos key executives?

    Prognos's key executives are Sundeep Bhan, Jason Bhan and Steve Chase.

  • How many employees does Prognos have?

    Prognos has 87 employees.

  • Who are Prognos competitors?

    Competitors of Prognos include Qventus, Examinetics and OM1.

  • Where is Prognos headquarters?

    Prognos headquarters is located at 85 Broad St, New York.

  • Where are Prognos offices?

    Prognos has an office in New York.

  • How many offices does Prognos have?

    Prognos has 1 office.